Sequential next generation sequencing analysis in homogeneously treated low risk NPM1-mutated acute myeloid leukemia with an adverse clinical outcome

Am J Hematol. 2022 Apr;97(4):E135-E138. doi: 10.1002/ajh.26469. Epub 2022 Jan 24.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • High-Throughput Nucleotide Sequencing*
  • Humans
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / therapy
  • Mutation
  • Nuclear Proteins / genetics
  • Prognosis

Substances

  • Nuclear Proteins